(R)-(-)-JQ1 Enantiomer

Cat. No.: HY-13030A

CAS No.: 1268524-71-5

Molecular Formula: $C_{23}H_{25}ClN_4O_2S$

Molecular Weight: 456.99

Target: Epigenetic Reader Domain

Pathway: Epigenetics

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (218.82 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.1882 mL	10.9412 mL	21.8823 mL
5 mM	0.4376 mL	2.1882 mL	4.3765 mL
10 mM	0.2188 mL	1.0941 mL	2.1882 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.75 mg/mL (6.02 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.75 mg/mL (6.02 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.75 mg/mL (6.02 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

(R)-(-)-JQ1 Enantiomer is the stereoisomer of (+)-JQ1. (+)-JQ1 potently decreases expression of both BRD4 target genes, whereas (R)-(-)-JQ1 Enantiomer has no effect.

IC_{50} & Target

BET bromodomain[1]

In Vitro

(R)-(-)-JQ1 Enantiomer shows no significant interaction with any bromodomain. Besides, (R)-(-)-JQ1 Enantiomer is

comparatively inactive in nuclear protein in testis (NUT) midline carcinoma (NMC)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2961-2966.
- EMBO Mol Med. 2018 Apr;10(4). pii: e8163.
- Br J Pharmacol. 2020 Jul;177(13):2959-2973.
- Cell Death Dis. 2020 Jun 15;11(6):459.
- Front Pharmacol. 2020 Jul 10;11:1043.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Filippakopoulos, et al. Selective inhibition of BET bromodomains. Nature. 2010 Dec 23;468(7327):1067-73.

[2]. Mahe M, et al. An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers. EMBO Mol Med. 2018 Apr;10(4). pii: e8163.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA